FDA's Departure of Vinay Prasad Exposes Systemic Flaws in Rare Disease Treatment Approvals
Original framing: “Vinay Prasad, key Makary ally and a focus of controversy at the FDA, is leaving the agency” — STAT News
The core of the article revolves around evidence‑based decision‑making and the tension between rigorous data and market pressure. It correctly foregrounds the need for transparent, reproducible science in rare‑disease approvals. This dimension is the strongest in the piece.
The departure of Vinay Prasad spotlights a regulatory system that leans heavily on scientific rigor yet neglects Indigenous wisdom, historical lessons, and marginalized patient narratives.
By weaving cross‑cultural insights, artistic empathy, and trickster irony into a future‑oriented, evidence‑rich framework, the FDA can transform its rare‑disease approval process into a more inclusive, transparent, and adaptable institution. Such a systemic shift requires independent review bodies, real‑world evidence mandates, international learning networks, and robust scenario planning to align market forces with genuine health outcomes.